The U.S. Food and Drug Administration has issued an urgent warning for users of certain Abbott diabetes monitors to immediately stop using the devices after they were linked to seven deaths and more than 700 injuries worldwide.
The warning, announced Wednesday, specifically targets certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose monitoring sensors manufactured by Abbott Diabetes Care. The affected devices have reportedly been providing dangerously inaccurate low glucose readings that could lead patients to make potentially fatal treatment decisions.
“These decisions may pose serious health risks, including potential injury or death,” the FDA warned in its safety communication.
Which devices are affected?
The recall specifically involves FreeStyle Libre 3 sensors with model numbers 72080-01 (unique device identifiers 00357599818005 and 00357599819002) and FreeStyle Libre 3 Plus sensors with model numbers 78768-01 and 78769-01 (unique device identifiers 00357599844011 and 00357599843014).
Importantly, other FreeStyle Libre products aren’t included in this safety alert. The FDA indicates that approximately three million sensors in the United States from a single production line are affected, though about half have already expired or been used.
A growing toll of injuries
The situation appears particularly dire internationally. As of November 14, seven deaths have been reported worldwide, alongside 736 serious adverse events connected to the faulty sensors. Within the U.S. specifically, 57 injuries have been documented, though thankfully no American deaths have been linked to the devices.
For diabetic patients, accurate glucose readings are literally a matter of life and death. The affected sensors may show incorrect low glucose readings, potentially causing patients to consume too many carbohydrates or skip needed insulin doses — decisions that can lead to dangerous health complications.
Abbott’s response
Abbott has notified customers of the problem and says it has identified and resolved the issue in the affected production lot. The company has established a website (www.FreeStyleCheck.com) where users can verify if their sensors might be affected and request replacements.
This isn’t the first safety concern for continuous glucose monitoring systems. Even with properly functioning sensors, Abbott already cautions that “The FreeStyle Libre 14 day Flash Glucose Monitoring System must be removed prior to Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or high-frequency electrical heat (diathermy) treatment.” Such procedures can damage the sensors and cause incorrect readings.
Still, continuous glucose monitors have revolutionized diabetes management for millions, allowing patients to track their blood sugar levels without repeated finger pricks throughout the day.
What users should do
The FDA’s guidance is unambiguous: stop using affected sensors immediately and discard them. Users should check their device against the recall information and contact their healthcare provider about alternative monitoring methods if their sensors are among those affected.
For the millions of Americans who rely on continuous glucose monitoring to manage their diabetes, this recall serves as a sobering reminder of their dependence on technology that, while life-changing, can also pose serious risks when it malfunctions.
